Several aptamers targeting the spike protein have been previously reported for COVID-19 diagnosis and therapeutic purposes, such as blocking the virus’s entry by preventing the interaction between the RBD region of the spike protein and angiotensin-converting enzyme-2 (ACE-2), a primary receptor on human epithelial cells.22 The gene discussed is ACE2; the disease is COVID-19.